On Tuesday, Elevation Oncology Inc (NASDAQ: ELEV) was -2.28% drop from the session before settling in for the closing price of $0.62. A 52-week range for ELEV has been $0.50 – $5.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 36.83%. With a float of $52.02 million, this company’s outstanding shares have now reached $59.12 million.
Considering the fact that the conglomerate employs 29 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 50.0%, operating margin of -72425.86%, and the pretax margin is -72250.0%.
Elevation Oncology Inc (ELEV) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Elevation Oncology Inc stocks. The insider ownership of Elevation Oncology Inc is 12.00%, while institutional ownership is 61.46%.
Elevation Oncology Inc (ELEV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.33% during the next five years compared to -52.56% drop over the previous five years of trading.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
You can see what Elevation Oncology Inc (ELEV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.89 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
Compared to the last year’s volume of 3.69 million, its volume of 1.27 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 19.60%. Additionally, its Average True Range was 0.07.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 22.65%, which indicates a significant increase from 11.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.91% in the past 14 days, which was lower than the 92.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6513, while its 200-day Moving Average is $1.5315. Nevertheless, the first resistance level for the watch stands at $0.6271 in the near term. At $0.6456, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6641. If the price goes on to break the first support level at $0.5901, it is likely to go to the next support level at $0.5716. Now, if the price goes above the second support level, the third support stands at $0.5531.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
There are 59,119K outstanding shares of the company, which has a market capitalization of 35.99 million. As of now, sales total 0 K while income totals -45,700 K. Its latest quarter income was 0 K while its last quarter net income were -12,880 K.
